Patient Square Capital, a healthcare investment firm, led a $226.5m Series C funding round in Apollo Therapeutics, a portfolio biopharmaceutical company focused on translating fundamental medical research into medicines through a hub-and-spoke approach. “We are delighted to announce the close of our latest fundraise and wish to thank our existing investors for their continued support, as well as warmly welcoming all the new investors. Apollo has built a broad and diversified pipeline focused on major commercial markets and this latest fund-raising enables us to take our most advanced programs to key clinical value inflection points,” Richard Mason, Apollo Therapeutics CEO.